VERTEX PHARMACEUTICALS INC / MA

For the period ended Jun 30, 2025. Filed Aug 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 5, 2025

VRTX$547.89-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Income (Loss)

(unaudited; in millions, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenues:
Product revenues, net	$2,944.0	$2,645.6	$5,704.2	$5,336.2
Other revenues	20.7	—	30.7	—
Total revenues	2,964.7	2,645.6	5,734.9	5,336.2
Costs and expenses:
Cost of sales	407.5	371.9	770.5	714.5
Research and development expenses	978.4	966.6	1,958.1	1,755.7
Acquired in-process research and development expenses	2.2	4,449.1	22.0	4,525.9
Selling, general and administrative expenses	424.6	372.2	821.0	714.9
Intangible asset impairment charge	—	—	379.0	—
Change in fair value of contingent consideration	0.9	0.5	3.1	0.4
Total costs and expenses	1,813.6	6,160.3	3,953.7	7,711.4
Income (loss) from operations	1,151.1	(3,514.7)	1,781.2	(2,375.2)
Interest income	122.4	156.5	243.3	337.7
Interest expense	(3.7)	(9.9)	(6.7)	(20.3)
Other income (expense), net	13.2	(23.1)	(4.4)	(54.3)
Income (loss) before provision for income taxes	1,283.0	(3,391.2)	2,013.4	(2,112.1)
Provision for income taxes	250.1	202.4	334.2	381.9
Net income (loss)	$1,032.9	$(3,593.6)	$1,679.2	$(2,494.0)
Net income (loss) per common share:
Basic	$4.02	$(13.92)	$6.54	$(9.66)
Diluted	$3.99	$(13.92)	$6.48	$(9.66)
Shares used in per share calculations:
Basic	256.7	258.1	256.8	258.1
Diluted	258.9	258.1	259.2	258.1

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.